Put another way, regular NSAIDs use is predicted to reduce CRC risk by 16% for those at low risk based on the TGF-β/GRHR pPRS and by 30% for those at high TGF-β/GRHR pPRS risk. The gene discussed is TGFB1; the disease is colorectal carcinoma.